Recorded January 21, 2020 | 7 p.m. CT
For children that have been diagnosed with polycystic kidney disease (PKD), it is important to understand the non-renal manifestations of the disease as well as how PKD affects the kidneys. Join us as Dr. Ryan Fischer discusses how the liver of children with ADPKD and ARPKD may be affected, including a look at congenital hepatic fibrosis (CHF). Dr. Fischer will address clinical management of liver complications and will answer your questions.
Ryan Fischer, M.D.
Pediatric Transplant Hepatologist | Children’s Mercy Hospital
Ryan Fischer is a board-certified Pediatric Gastroenterologist and Transplant Hepatologist at Children’s Mercy Hospital in Kansas City. Dr. Fischer has a strong interest in translational research related to liver disease and transplantation, and novel therapeutics to treat disordered inflammation in the liver. His background in the lab includes basic research in dendritic cell biology, antigen presentation and cell-based immunotherapy. In collaboration with the University of Kansas’s Department of Microbiology, Immunology and Genetics, he is working to harness the potential of regulatory T cells for the modulation of liver allograft rejection. Clinically, his focus is on the diagnosis and treatment of liver disease in children, with a great deal of time devoted to children that need or have undergone liver transplantation. The Children’s Mercy hepatology team specializes in fatty liver disease, drug-induced liver injury, progressive liver fibrosis, and liver disease related to congenital heart disease.
There are no studies currently studying CHF in children with PKD. However, check out these other opportunities to participate in research and help accelerate scientific discoveries
- Children’s National Health System’s ARPKD Database
- International Registry of children with PKD: ARegPKD
- Clinical study of tesevatinib in children with ARPKD
- An imaging study at Children’s Hospital of Philadelphia, and another at Cleveland Clinic Children’s